FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620006140> ?p ?o ?g. }

• W2620006140 endingPage "3475" @default.
• W2620006140 startingPage "3475" @default.
• W2620006140 abstract "Abstract Backgrounds: Allogeneic Hematopoietic Cell Transplantation (HCT) is a potentially curative treatment for fit patients with relapsed/refractory multiple myeloma (MM). When a HLA-identical donor is not available, haploidentical HCT (haploHCT) represents an acceptable therapeutic option, especially when post-transplant cyclophosphamide (PT-Cy) is used as anti-GVHD prophylaxis. Patients and methods: Twenty-nine patients (median age 56 years, range 47-70) undergoing myeloablative (n=15) or reduced-intensity (n=14) haploHCT from February 2011 to November 2015 are included in this retrospective analysis. The median number of previous lines of therapy was 2 (range 1-7) with 27 (93%) of patients having previously performed an autologous HCT. Both bortezomib and lenalidomide were used in 27 (92%) patients before haploHCT. Eighteen patients (62%) had chemosensitive disease at time of haploHCT (CR=4, VGPR=9, PR=5) and 11 (38%) had chemorefractory disease (PD=7, SD=4). Graft source was marrow-derived in 59% (n=17) and peripheral blood in 41% (n=12) of patients. Standard post-transplant cyclophosphamide anti-GVHD prophylaxis (50mg/mq day +3 and +4 or +5) plus mycophenolate and cyclosporine (n=24) or tacrolimus (n=3) or rapamycine (n=2) was used for the whole study cohort. Overall survival (OS) and Progression Free Survival (PFS) were performed with Kaplan-Meier analysis. Neutrophil and platelets engraftment, acute GVHD, chronic GVHD, Non-Relapse-Mortality (NRM) and Relapse Incidence/Progression of Disease (RI/POD) were obtained with competing risk analysis. Results: At day +30, neutrophil and platelets engraftments were 86% (95%CI:65-95) and 59% (95%CI:38-74), respectively. Acute GVHD grade >2 at days +100 and +180 were 38% (95%CI: 20-55%) and 41% (95%CI: 23-59%), respectively. All grade chronic GVHD at 12 and 18 months was 21% (95%CI: 8-37. At 18 months, RI/POD was 39% (95%CI:20-58%) and NRM 15% (CI95%:5-32). With a median follow-up in survivors of 16 months (range 5-55 months), the 18-month OS and PFS were 68% (95%CI: 47-82%) and 34% (95%CI: 15-54%), respectively. Chemorefractory disease at transplant was associated with a worse 18-month RI/POD (70% vs 18%, p=<0.01) and a markedly reduced PFS (9% vs 57%, p=0.04) and OS (53% vs 78%, p=<0.01) (Figure 1). Survival outcomes were similar between marrow-derived and peripheral blood graft source cohorts. Conclusions: HaploHCT is a feasible and effective strategy in patients with relapsed/refractory high-risk multiple myeloma. Chemorefractory disease at transplant was the only prognostic factor associated with a significant reduced RI/POD, PFS and OS. Figure Kaplan-Meier estimates of progression free survival from time of transplant of the chemosensitive and chemorefractory disease. Figure. Kaplan-Meier estimates of progression free survival from time of transplant of the chemosensitive and chemorefractory disease. Disclosures No relevant conflicts of interest to declare." @default.
• W2620006140 created "2017-06-05" @default.
• W2620006140 creator A5006314162 @default.
• W2620006140 creator A5021060422 @default.
• W2620006140 creator A5022161221 @default.
• W2620006140 creator A5023466579 @default.
• W2620006140 creator A5053560614 @default.
• W2620006140 creator A5055226769 @default.
• W2620006140 creator A5059403965 @default.
• W2620006140 creator A5064079562 @default.
• W2620006140 creator A5068769311 @default.
• W2620006140 creator A5076929140 @default.
• W2620006140 creator A5083379505 @default.
• W2620006140 creator A5091566972 @default.
• W2620006140 date "2016-12-02" @default.
• W2620006140 modified "2023-09-27" @default.
• W2620006140 title "Unmanipulated Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide Anti-Gvhd Prophylaxis" @default.
• W2620006140 doi "https://doi.org/10.1182/blood.v128.22.3475.3475" @default.
• W2620006140 hasPublicationYear "2016" @default.
• W2620006140 type Work @default.
• W2620006140 sameAs 2620006140 @default.
• W2620006140 citedByCount "1" @default.
• W2620006140 countsByYear W26200061402018 @default.
• W2620006140 crossrefType "journal-article" @default.
• W2620006140 hasAuthorship W2620006140A5006314162 @default.
• W2620006140 hasAuthorship W2620006140A5021060422 @default.
• W2620006140 hasAuthorship W2620006140A5022161221 @default.
• W2620006140 hasAuthorship W2620006140A5023466579 @default.
• W2620006140 hasAuthorship W2620006140A5053560614 @default.
• W2620006140 hasAuthorship W2620006140A5055226769 @default.
• W2620006140 hasAuthorship W2620006140A5059403965 @default.
• W2620006140 hasAuthorship W2620006140A5064079562 @default.
• W2620006140 hasAuthorship W2620006140A5068769311 @default.
• W2620006140 hasAuthorship W2620006140A5076929140 @default.
• W2620006140 hasAuthorship W2620006140A5083379505 @default.
• W2620006140 hasAuthorship W2620006140A5091566972 @default.
• W2620006140 hasConcept C126322002 @default.
• W2620006140 hasConcept C141071460 @default.
• W2620006140 hasConcept C143998085 @default.
• W2620006140 hasConcept C2776364478 @default.
• W2620006140 hasConcept C2776694085 @default.
• W2620006140 hasConcept C2776755627 @default.
• W2620006140 hasConcept C2777408962 @default.
• W2620006140 hasConcept C2777478702 @default.
• W2620006140 hasConcept C2779263901 @default.
• W2620006140 hasConcept C2779972918 @default.
• W2620006140 hasConcept C2909675724 @default.
• W2620006140 hasConcept C2911091166 @default.
• W2620006140 hasConcept C71924100 @default.
• W2620006140 hasConcept C88879693 @default.
• W2620006140 hasConcept C90924648 @default.
• W2620006140 hasConceptScore W2620006140C126322002 @default.
• W2620006140 hasConceptScore W2620006140C141071460 @default.
• W2620006140 hasConceptScore W2620006140C143998085 @default.
• W2620006140 hasConceptScore W2620006140C2776364478 @default.
• W2620006140 hasConceptScore W2620006140C2776694085 @default.
• W2620006140 hasConceptScore W2620006140C2776755627 @default.
• W2620006140 hasConceptScore W2620006140C2777408962 @default.
• W2620006140 hasConceptScore W2620006140C2777478702 @default.
• W2620006140 hasConceptScore W2620006140C2779263901 @default.
• W2620006140 hasConceptScore W2620006140C2779972918 @default.
• W2620006140 hasConceptScore W2620006140C2909675724 @default.
• W2620006140 hasConceptScore W2620006140C2911091166 @default.
• W2620006140 hasConceptScore W2620006140C71924100 @default.
• W2620006140 hasConceptScore W2620006140C88879693 @default.
• W2620006140 hasConceptScore W2620006140C90924648 @default.
• W2620006140 hasIssue "22" @default.
• W2620006140 hasLocation W26200061401 @default.
• W2620006140 hasOpenAccess W2620006140 @default.
• W2620006140 hasPrimaryLocation W26200061401 @default.
• W2620006140 hasRelatedWork W1955322177 @default.
• W2620006140 hasRelatedWork W1972184826 @default.
• W2620006140 hasRelatedWork W2142493118 @default.
• W2620006140 hasRelatedWork W2163095305 @default.
• W2620006140 hasRelatedWork W2252670258 @default.
• W2620006140 hasRelatedWork W2560664961 @default.
• W2620006140 hasRelatedWork W2627028277 @default.
• W2620006140 hasRelatedWork W2912805204 @default.
• W2620006140 hasRelatedWork W3198847730 @default.
• W2620006140 hasRelatedWork W3212134050 @default.
• W2620006140 hasVolume "128" @default.
• W2620006140 isParatext "false" @default.
• W2620006140 isRetracted "false" @default.
• W2620006140 magId "2620006140" @default.
• W2620006140 workType "article" @default.